- Home
- ALV vs SYRE Comparison
ALV vs SYRE Comparison
Compare ALV & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALV | SYRE |
|---|---|---|
| Founded | 1953 | 2013 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.7B |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALV | SYRE |
|---|---|---|
| Price | $115.74 | $98.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 18 |
| Target Price | ★ $131.38 | $122.33 |
| AVG Volume (30 Days) | 752.2K | ★ 1.3M |
| Earning Date | 10-23-2026 | 11-10-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 5.36 | N/A |
| Revenue | ★ $10,815,000,000.00 | N/A |
| Revenue This Year | $2.44 | N/A |
| Revenue Next Year | $2.35 | N/A |
| P/E Ratio | $21.57 | ★ N/A |
| Revenue Growth | ★ 4.09 | N/A |
| 52 Week Low | $99.16 | $21.15 |
| 52 Week High | $132.17 | $110.18 |
Technical Indicators
Market Signals| Indicator | ALV | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 62.90 |
| Support Level | $113.85 | $93.45 |
| Resistance Level | $126.05 | $105.09 |
| Average True Range (ATR) | 2.78 | 4.41 |
| MACD | 0.52 | 1.77 |
| Stochastic Oscillator | 71.86 | 97.51 |
Price Performance
Historical ComparisonAbout ALV Autoliv Inc.
Autoliv Inc is a developer, manufacturer, and supplier of passive safety systems to the automotive industry with a broad range of product offerings. Its product portfolio includes passive safety systems for commercial vehicles, battery cut-off switches, safety solutions for riders of motorcycles and bikes, airbags (including steering wheels and inflators), seatbelts, etc. Geographically, the group operates in the Americas, Europe, China, and Asia, excluding China, of which the maximum revenue is generated from its business in the Americas.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.